Immunomedics IncFind Ratings Reports
IMMUNOMEDICS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. IMMUNOMEDICS INC is extremely liquid. Currently, the Quick Ratio is 4.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 929.03% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||0.9||1.18|
|Net Income ($mil)||-14.0||-11.76|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||61.58||106.19|
|Total Assets ($mil)||67.64||111.83|
|Total Debt ($mil)||97.17||96.44|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||-1601.45||-930.54|
|Return on Assets||-82.1||-42.42|
|Return on Equity||0.0||-887.56|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||94.8||93.45|
|Div / share||0.0||0.0|
|Book value / share||-0.47||0.06|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2510566.0||891527.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|IMMU NM||Peers 40.39||IMMU NM||Peers 21.72|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
IMMU's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
IMMU's P/CF is negative making the measure meaningless.
|IMMU NM||Peers 122.62||IMMU NA||Peers 1.15|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
IMMU's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|IMMU NM||Peers 11.16||IMMU -15.68||Peers -19.12|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
IMMU's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, IMMU is expected to significantly trail its peers on the basis of its earnings growth rate.
|IMMU 52.24||Peers 425.82||IMMU 5.69||Peers 40.81|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
IMMU is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
IMMU significantly trails its peers on the basis of sales growth